In line with this finding, another research group identified the so-called multiple low dose (MLD) therapy with RAF (RAFi) and ERKi as part of either a triple or quadruple vertical combination therapy to be effective in a lung cancer mouse model leading to significant tumor regression without causing major toxicities or acquired resistance in specific patient subsets (224). The gene discussed is RAF1; the disease is lung cancer.